전남대학교 중앙도서관

Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial.

issue: Research square [Res Sq] 2023 Feb 08. Date of Electronic Publication: 2023 Feb 08.
Author: Parry MA; Cancer Institute, University College London; London, UK.
Grist E; Cancer Institute, University College London; London, UK.
Mendes L; Cancer Institute, University College London; London, UK.
Dutey-Magni P; MRC Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, University College London; London, UK.
Sachdeva A; Genito-Urinary Cancer Research Group, Division of Cancer Sciences, Manchester Cancer Research Centre, The University of Manchester; Manchester, UK.
Brawley C; MRC Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, University College London; London, UK.
Murphy L; MRC Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, University College London; London, UK.
Proudfoot J; Veracyte, Inc; San Diego, USA.
Lall S; Cancer Institute, University College London; London, UK.
Liu Y; Veracyte, Inc; San Diego, USA.
Friedrich S; Cancer Institute, University College London; London, UK.
Ismail M; Cancer Institute, University College London; London, UK.
Hoyle A; Genito-Urinary Cancer Research Group, Division of Cancer Sciences, Manchester Cancer Research Centre, The University of Manchester; Manchester, UK.; Department of Surgery, The Christie and Salford Royal Hospitals; Manchester, UK.
Ali A; Genito-Urinary Cancer Research Group, Division of Cancer Sciences, Manchester Cancer Research Centre, The University of Manchester; Manchester, UK.
Haran A; Genito-Urinary Cancer Research Group, Division of Cancer Sciences, Manchester Cancer Research Centre, The University of Manchester; Manchester, UK.; Department of Surgery, The Christie and Salford Royal Hospitals; Manchester, UK.
Wingate A; Cancer Institute, University College London; London, UK.
Zakka L; Cancer Institute, University College London; London, UK.
Wetterskog D; Cancer Institute, University College London; London, UK.
Amos CL; MRC Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, University College London; London, UK.
Atako NB; MRC Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, University College London; London, UK.
Wang V; Department of Data Science, Dana-Farber Cancer Institute; Boston, USA.
Rush HL; MRC Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, University College London; London, UK.
Jones RJ; University of Glasgow, Beatson West of Scotland Cancer Centre; Glasgow, UK.
Leung H; University of Glasgow, Beatson West of Scotland Cancer Centre; Glasgow, UK.
Cross WR; St James's University Hospital; Leeds, UK.
Gillessen S; Istituto Oncologico della Svizzera Italiana, EOC; Bellinzona, Switzerland.; Università della Svizzera Italiana; Lugano, Switzerland.
Parker CC; Royal Marsden NHS Foundation Trust and Institute of Cancer Research; London, UK.
Chowdhury S; Guy's and St Thomas' NHS Foundation Trust; London, UK.
Lotan T; Johns Hopkins University School of Medicine; Baltimore, USA.
Marafioti T; Cancer Institute, University College London; London, UK.
Urbanucci A; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital; Oslo, Norway.; Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere University Hospital; Tampere, Finland.
Schaeffer EM; Department of Urology, Northwestern University Feinberg School of Medicine; Chicago, USA.
Spratt DE; Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center; Cleveland, USA.
Waugh D; Queensland University of Technology; Brisbane, Australia.
Powles T; Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London; London, UK.
Berney DM; Barts Cancer Institute, Queen Mary University of London; London, UK.
Sydes MR; MRC Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, University College London; London, UK.
Parmar MKB; MRC Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, University College London; London, UK.
Hamid AA; Department of Medical Oncology, Dana-Farber Cancer Institute; Boston, USA.
Feng FY; University of California San Francisco; San Francisco, USA.
Sweeney CJ; Department of Medical Oncology, Dana-Farber Cancer Institute; Boston, USA.
Davicioni E; Veracyte, Inc; San Diego, USA.
Clarke NW; Genito-Urinary Cancer Research Group, Division of Cancer Sciences, Manchester Cancer Research Centre, The University of Manchester; Manchester, UK.; Department of Surgery, The Christie and Salford Royal Hospitals; Manchester, UK.
James ND; Royal Marsden NHS Foundation Trust and Institute of Cancer Research; London, UK.
Brown LC; MRC Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, University College London; London, UK.
Attard G; Cancer Institute, University College London; London, UK.
DB Label: Database : MEDLINE

링크메뉴

주메뉴

전자자료 상세검색

전자자료 상세검색

전체선택